<DOC>
	<DOCNO>NCT02305641</DOCNO>
	<brief_summary>This phase IV , prospective , multicenter , non-interventional study ( regulatory post-marketing surveillance ) approximately 3,000 patient receive Kadcyla ( trastuzumab emtansine ) . Patients HER2-positive , unresectable locally advanced metastatic breast cancer , receive prior treatment trastuzumab taxane , administer Kadcyla infusion physician 's discretion register surveillance Korea . Patients ask provide informed consent ; data collect electronic Case Report Forms approximately 6 year .</brief_summary>
	<brief_title>An Observational Study Kadcyla Safety Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<criteria>Patients HER2positive , unresectable locally advanced metastatic breast cancer , receive prior treatment trastuzumab taxane Hypersensitivity Kadcyla ingredient product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>